Papers in BMJ Oncology
Page 4 · newest first
- Feasibility of implementing a rapid-learning methodology to inform radiotherapy treatments: key professional stakeholders’ viewsBMJ Oncology · 2024
- Challenges faced by women oncologists in Africa: a mixed methods studyBMJ Oncology · 2024
- Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trialsBMJ Oncology · 2024
- HealthCare Access Barrier (HCAB) framework for the barriers to cancer care during conflicts: perspective from IraqBMJ Oncology · 2024
- Embracing rapid learning in radiotherapy: feasible and acceptable with stakeholder corroborationBMJ Oncology · 2024
- Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid reviewBMJ Oncology · 2024
- Accuracy of screening tests for cervical precancer in women living with HIV in low-resource settings: a paired prospective study in Lusaka, ZambiaBMJ Oncology · 2024
- Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunityBMJ Oncology · 2024
- Identifying the deficits in cancer care for people with intellectual disabilitiesBMJ Oncology · 2024
- Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapyBMJ Oncology · 2024
- Cervical cancer screening using tests that provide same-day results: a study of test accuracyBMJ Oncology · 2024
- Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancerBMJ Oncology · 2024
- Artificial intelligence across oncology specialties: current applications and emerging toolsBMJ Oncology · 2024
- Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spendingBMJ Oncology · 2024
- Multi-cancer early detection tests: a strategy for improvementBMJ Oncology · 2024
- Repurposing radiosensitising medicines for radiotherapy: an overviewBMJ Oncology · 2024
- ‘Godrevy Project’: virtual reality for symptom control and well-being in oncology and palliative care – a non-randomised pre-post interventional trialBMJ Oncology · 2023
- Benefits and harms of breast cancer screening revisited: a large, retrospective cross-sectional study quantifying treatment intensity in women with screen-detected versus non-screen-detected cancer in Australia and New ZealandBMJ Oncology · 2023
- Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trialBMJ Oncology · 2023
- Boosting and broadening recruitment to UK cancer trials: towards a blueprint for actionBMJ Oncology · 2023
- PACT-UK (PAncreatic Cancer reporting Template–UK): a cross-specialty multi-institutional consensus panel development of a standardised radiological reporting proforma for pancreatic cancerBMJ Oncology · 2023
- How do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?BMJ Oncology · 2023
- Closing the gaps in recruitment and retention in cancer trials: sufficient evidence but poor implementationBMJ Oncology · 2023
- Cardiovascular health: an important component of cancer survivorshipBMJ Oncology · 2023
- The English National Lynch Syndrome transformation project: an NHS Genomic Medicine Service Alliance (GMSA) programmeBMJ Oncology · 2023
- NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)BMJ Oncology · 2023
- Transforming the care of people with Lynch syndrome: a system-wide approachBMJ Oncology · 2023
- Globalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threats and opportunitiesBMJ Oncology · 2023
- Globalisation of clinical trials in oncology: a double-edged sword?BMJ Oncology · 2023
- Treatment-related acute toxicity with adjuvant systemic treatment among patients with HER2-positive early invasive breast cancer: a national population-based cohort studyBMJ Oncology · 2023
- Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort studyBMJ Oncology · 2023
- Use of immunosuppression and subsequent cancer incidence: cohort studyBMJ Oncology · 2023
- Guilty by association? The complex relationship between immunosuppressants and cancerBMJ Oncology · 2023
- Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019BMJ Oncology · 2023
- Long-term opioid therapy trajectories and overdose in patients with and without cancerBMJ Oncology · 2023
- Shifting tides: the rising tide of early-onset cancers demands attentionBMJ Oncology · 2023
- Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPathBMJ Oncology · 2023
- Community-generated solutions to cancer inequity: recommendations from transgender, non-binary and intersex people on improving cancer screening and careBMJ Oncology · 2023
- Inclusive oncological trials and targeted treatments cannot ignore sex and genderBMJ Oncology · 2023
- Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gapsBMJ Oncology · 2023
- Modern cancer trials still lack information about QoL impacts on patientsBMJ Oncology · 2023
- Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research studyBMJ Oncology · 2023
- COVID-19 and cancer in the UK: which will prove to be the lesser of two evils?BMJ Oncology · 2023
- Bridging the gap: promoting equity and diversity in global oncology research within Sub-Saharan AfricaBMJ Oncology · 2023